Lynne Fahey McGrath
CIK: 0001866270
Lynne Fahey McGrath's purchase track record
Lynne Fahey McGrath has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 3/22/2023 | ALZN | $4K | +57.0% | -47.4% | +11.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ALZN | ▼ Sell | Open Market | 30 | $69 | 10/23/2025 | View on chart |
| ALZN | ▲ Buy | Open Market | 10,000 | $4K | 3/22/2023 | View on chart |
| ALZN | ▼ Sell | Open Market | 25,000 | $30K | 3/28/2022 | View on chart |
| ALZN | ▲ Buy | Option Exercise | 50,000 | $0 | 3/15/2022 | View on chart |
| ALZN | ▲ Buy | Option Exercise | 47,222 | $0 | 10/15/2021 | View on chart |
| ALZN | ▲ Buy | Option Exercise | 2,778 | $0 | 9/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 9, 2026
Alzamend Neuro (ALZN) Receives Analyst Upgrade
Alzamend Neuro received an upgrade to a buy rating from an analyst. This move aligns with the firm's price target of $26.00, which is significantly higher than the stock's 52-week range of $0.84 to $2.68. The upgrade provides a positive signal for the company's outlook, although the stock currently trades near its support level.
Alzamend Neuro (ALZN) Receives Analyst Upgrade. Alzamend Neuro received an upgrade to a buy rating from an analyst. This move aligns with the firm's price target of $26.00, which is significantly higher than the stock's 52-week range of $0.84 to $2.68. The upgrade provides a positive signal for the company's outlook, although the stock currently trades near its support level.